Letrozole is a non-steroidal competitive inhibitor of the aromatase enzyme system; it inhibits the conversion of androgens to oestrogens. In adult non-tumour- and tumour-bearing female animals, letrozole is as effective as ovariectomy in reducing uterine weight, elevating serum luteinizing hormone (LH), and causing the regression of oestrogen-dependent tumours. In contrast to ovariectomy, treatment with letrozole does not lead to an increase in serum follicle-stimulating hormone (FSH). Letrozole selectively inhibits gonadal steroidogenesis but has no significant effect on adrenal mineralocorticoid or glucocorticoid synthesis.
Fempro (Letrozole) inhibits the aromatase enzyme by competitively binding to the haem of the cytochrome (CY) P450 subunit of the enzyme, resulting in a reduction of oestrogen biosynthesis in all tissues. Treatment of women with letrozole significantly lowers serum oestrone, oestradiol and oestrone sulphate and has not been shown to significantly affect adrenal corticosteroid synthesis, aldosterone synthesis or the synthesis of thyroid hormones.
Fempro (Letrozole) is used to treat breast cancer in women who have gone through menopause (time in life when a woman ceases to have a menstrual period). It is also used to prevent cancer reoccurrence or spreading to other parts of the body or after 5 years of tamoxifen therapy.
Fempro (Letrozole) belongs to class of medications called non-steroidal aromatase inhibitors. Fempro reduces the amount of estrogen (female sex hormone) by blocking an enzyme (aromatase), thereby stopping the growth of breast cancer or its spreading to other parts of the body.
Vomiting, Nausea, Night sweats, Ankle swelling, Limb swelling, Muscle pain, Bone pain, Joint pain, Blurred vision, Breast pain, Change in body weight, Constipation, Diarrhoea, Dizziness, Fatigue, Hair loss, Headache, Heartburn, Hot flashes, Insomnia, Loss of appetite, Stomach pain, Vaginal bleeding, Weakness